SKIN Stock Forecast & Price Target

The Beauty Health Company reported a year-over-year sales increase of 1.8% in its consumables business, reaching $57.7 million, demonstrating consumers' ongoing willingness to invest in aesthetic treatments, albeit with a more selective approach. Additionally, the management underscored a significant 10% rise in average spending per treatment in the U.S., driven by the popularity of premium boosters, which are expected to enhance both consumer satisfaction and order sizes. Furthermore, effective operational expense management led to a notable leverage improvement, reducing operating expenses to 64.2% of sales, which signifies the company's focus on cost control and strategic shifts, especially in the competitive China market.

The Beauty Health Company has exhibited a concerning decline in core delivery systems, with new placements falling over 30% year-over-year and quarter-over-quarter, significantly missing prior estimates. This deceleration in new system placements poses risks to future consumables sales, which are essential for the company's profitability targets in 2024. Additionally, while consumables sales showed slight growth of 1.8% year-over-year, the overall revenue from delivery systems decreased by 7.8%, indicating ongoing challenges in the macroeconomic environment and reduced consumer demand, particularly in the Chinese market.